News

December 12, 2018

Imfinzi Falls Short in Prolonging Overall Survival of Metastatic NSCLC Patients, Phase 3 Trial Shows

News

Treatment with Imfinzi (durvalumab), with or without the investigational immunotherapy tremelimumab, failed to extend the survival of patients with metastatic non-small cell lung cancer (NSCLC) compared with standard chemotherapy in a ... Read more

December 11, 2018

FDA Approves Tecentriq Combo as Initial Treatment for Select Patients with Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab), in combination with Avastin (bevacizumab) and the chemotherapies Taxol (paclitaxel) and carboplatin, for a first-line treatment of certain patients with metastatic non-squamous non-small ... Read more

December 7, 2018December 7, 2018

BioLineRx‘s Immunotherapy AGI-134 Receives FDA’s Biological Product Designation

News

The U.S. Food and Drug Administration has granted BioLineRx’s investigational immunotherapy AGI-134 a biological product designation, making the company eligible for 12-year market exclusivity after the treatment is approved in the ... Read more

December 5, 2018December 5, 2018

Opdivo-Chemo Combo Doubles Survival Rates in Relapsed or Refractory Leukemia Patients, Phase 2 Trial Shows

News

A combination of Opdivo (nivolumab) and standard Vidaza (azacitidine) chemotherapy reduced the tumor burden in one-third of acute myeloid leukemia (AML) patients and doubled survival rates over patients treated with Vidaza ... Read more

December 4, 2018

Yervoy, Local Injection of Candidate Therapy Tilsotolimod Shrink Advanced Melanoma Tumors, Trial Shows

News

A combination of Yervoy (ipilimumab) and Idera Pharmaceuticals’ investigational tilsotolimod reduced tumors in four out of 10 advanced melanoma patients included in a Phase 1/2 trial. Findings from the ILLUMINATE-204 trial (NCT02644967) were presented at the European Society ... Read more

November 30, 2018November 30, 2018

Tavo Reverses Resistance to PD-1 Inhibitors in Metastatic Melanoma, Phase 2b Trial Suggests

News

A combination of Tavo (tavokinogene telseplasmid/IL-12) and Keytruda (pembrolizumab) was effective at reducing tumors in advanced melanoma patients who had failed prior anti-PD-1 therapies, according to early results of a Phase ... Read more

November 28, 2018

Opdivo Cancer Treatment Safe for HIV Patients on Antiretrovirals, Study Suggests

News

Patients with human immunodeficiency virus (HIV) may safely receive immune checkpoint inhibitors as a cancer treatment, as long as they continue taking antiretroviral therapies, a retrospective study shows. Findings from ... Read more

November 27, 2018November 27, 2018

Opdivo-Yervoy Combo Delays Need for Additional Treatment in Renal Cell Carcinoma Patients, Phase 3 Data Shows

News

A combination of Opdivo (nivoumab) and Yervoy (ipilimumab) significantly delayed the need for a subsequent treatment in patients with advanced or metastatic renal cell carcinoma who had not previously been ... Read more

November 21, 2018November 21, 2018

Opdivo-Yervoy Combo Shows Durable Survival Benefits for Advanced Melanoma Patients in Phase 3 Trial

News

A combination of Bristol-Meyer Squibb‘s Opdivo (nivolumab) and Yervoy (ipilimumab) is more effective than either of the treatments alone as a first-line therapy for patients with advanced melanoma, according to ... Read more

November 20, 2018November 20, 2018

Celyad’s CAR T-Cell Therapy, CYAD-01, Showing Early Signs of Efficacy in Advanced Colorectal Cancer

News

CYAD-01 — Celyad‘s CAR T-cell product — is showing promise as a treatment for metastatic colorectal cancer patients (mCRC), both alone and in combination with standard of care chemotherapy, according to ... Read more